Home › Health › The FDA declined to approve one of biotech’s most...
Health

The FDA declined to approve one of biotech’s most closely watched cancer drugs

The FDA declined to approve one of biotech’s most closely watched cancer drugs
Key Points

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.

The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
FDA (ORG) Summit Therapeutics (ORG)
Originally published by MarketWatch Read original →